-         Consent to publish

The authors read and approved the final manuscript and agree to publish.

-         Availability of data and materials

-         Competing interests

-         Funding

MOST: 105-2314-B-182-050-MY3 and MOST 106-2314-B-182A-156-MY3 from the Ministry of Science and Technology of Taiwan and CMRPG8G0272 from Chang Gung Memorial Hospital in Taiwan. Although these institutes provided financial support, they had no influence on the way we collected, analyzed, or interpreted the data or wrote this manuscript.

-        Authors’ Contributions

YJS participated in draft the manuscript. HCK participated in its design and coordination.

References:

1. Wang, H., et al., Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin. Arthritis Rheumatol, 2015.67 (12): p. 3190-200.

2. Liu, L., et al., Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: Evidence on health outcomes and antidiabetic treatment in United States adults. World J Diabetes, 2016. 7 (18): p. 449-461.

3. Lin, C.C., et al., Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc, 2005.104 (3): p. 157-63.

4. Sung, S.F., et al., Validity of a stroke severity index for administrative claims data research: a retrospective cohort study. BMC Health Serv Res, 2016. 16 (1): p. 509.

5. Damjanov, N., M.T. Nurmohamed, and Z. Szekanecz, Biologics, cardiovascular effects and cancer. BMC Med, 2014. 12 : p. 48.

6. Ursini, F., et al., The effect of non-TNF-targeted biologics and small molecules on insulin resistance in inflammatory arthritis.Autoimmun Rev, 2018. 17 (4): p. 399-404.

7. Killinger, Z., et al., Biologic treatment in comparison to methotrexate has positive effect on trabecular bone score in rheumatoid arthritis patients: 1-year follow-up. Acta Clin Belg, 2018: p. 1-5.

8. Zerbini, C.A.F., et al., Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int, 2017. 28 (2): p. 429-446.

9. Maneiro, J.R., A. Souto, and J.J. Gomez-Reino, Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.Semin Arthritis Rheum, 2017. 47 (2): p. 149-156.

10. Wilton, K.M. and E.L. Matteson, Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis.Rheumatol Ther, 2017. 4 (2): p. 333-347.

11. Ramiro, S., et al., Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis, 2017. 76 (6): p. 1101-1136.

12. Kourbeti, I.S., P.D. Ziakas, and E. Mylonakis, Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis, 2014. 58 (12): p. 1649-57.

13. Furst, D.E., The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum, 2010. 39 (5): p. 327-46.

14. Barnabe, C., et al., Sex differences in pain scores and localization in inflammatory arthritis: a systematic review and metaanalysis. J Rheumatol, 2012. 39 (6): p. 1221-30.

15. Kamata, Y. and S. Minota, Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using ”National Database of Health Insurance Claims and Specific Health Checkups of Japan”. Rheumatol Int, 2018. 38 (4): p. 663-668.

16. Stoll, M.L. and A.C. Gotte, Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics, 2008. 2 (2): p. 229-52.

17. Borren, N.Z. and A.N. Ananthakrishnan, Safety of Biologic Therapy in Older Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol, 2019.

18. Singh, J.A., et al., Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet, 2015. 386 (9990): p. 258-65.

19. Rutherford, A.I., et al., Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford), 2018. 57 (6): p. 997-1001.

20. Bruce, E.S., et al., Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor alpha: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford), 2016. 55 (7): p. 1336-7.

21. Yun, H., et al., Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.Arthritis Care Res (Hoboken), 2015. 67 (5): p. 731-6.

22. Salliot, C., M. Dougados, and L. Gossec, Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis, 2009. 68 (1): p. 25-32.

23. Liao, H., et al., Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis, 2017.20 (2): p. 161-168.

24. Hussain, M.I., et al., Acute renal failure and metformin-associated lactic acidosis following colonoscopy. Diabetes Res Clin Pract, 2014. 105 (1): p. e6-8.

25. Adam, W.R. and R.C. O’Brien, A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure. Diabet Med, 2014. 31 (9): p. 1032-8.

26. Accortt, N.A., et al., Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations. Int J Chron Obstruct Pulmon Dis, 2017.12 : p. 2085-2094.

27. de La Forest Divonne, M., J.E. Gottenberg, and C. Salliot,Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers.Joint Bone Spine, 2017. 84 (2): p. 133-140.

28. Hsu, C.S., et al., Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan. Hepatol Int, 2018. 12 (6): p. 531-543.

29. Scott, I.C., S.L. Hider, and D.L. Scott, Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk? Drug Saf, 2018. 41 (7): p. 645-653.

30. Frost, A.E., et al., Giant cell interstitial pneumonitis. Disease recurrence in the transplanted lung. Am Rev Respir Dis, 1993.148 (5): p. 1401-4.

31. Holdsworth, S., et al., The clinical spectrum of acute glomerulonephritis and lung haemorrhage (Goodpasture’s syndrome). Q J Med, 1985. 55 (216): p. 75-86.

32. England, B.R., et al., Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival. Clin Rheumatol, 2018. 37 (11): p. 2907-2915.

33. Fernandez-Diaz, C., et al., Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Semin Arthritis Rheum, 2018.48 (1): p. 22-27.

34. Druce, K.L., et al., Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic. RMD Open, 2017. 3 (1): p. e000473.

35. Roubille, C. and B. Haraoui, Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum, 2014.43 (5): p. 613-26.